Teva Makes A Specialty M&A Play In Deal To Buy Auspex
This article was originally published in The Pink Sheet Daily
Executive Summary
The Israeli generic drug company will gain a lead drug in development for movement disorders, including chorea associated with Huntington’s disease, with the $3.5 billion acquisition of Auspex Pharmaceuticals.
You may also be interested in...
Keeping Track: Teva's Austedo Clears US FDA, Merck Sitagliptin CV Outcomes Labeling Draws Complete Response
The latest drug development news and highlights from our FDA Performance Tracker.
Teva’s Austedo Positioned To Compete With A Generic Rival
FDA approved Teva’s Austedo (deutetrabenazine) for chorea associated with Huntington’s disease, with a warning on depression and suicidality similar to generic Xenazine, but other parts of the labeling points to advantages.
Teva Preps For SD-809 Tardive Dyskinesia Filing By The End Of 2016
A second Phase III study testing the VMAT2 inhibitor in the indication was positive, positioning Teva for a neck-and-neck race to market against Neurocrine.